The unifying theme of the revised, competing renewal of this Program Project is a cellular and molecular approach to developmental neurology in an attempt to uncover processes leading to neonatal brain injury and mental retardation. Four inter-related projects are planned. They all concern the influence of overstimulation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor and related signaling pathways to neuronal damage during hypoxic-ischemic brain injury and AIDS. Hypoxic -ischemic insults are known to result in mental retardation and developmental delay. Only recently, however, has it become apparent that AIDS is associated with an approximately 50% incidence in delayed milestones and frank cognitive decline in children infected with HIV-1. This Program Project Group of Investigators and others have shown that at least part of this damage to the nervous system appears to be mediated by excessive NMDA receptor activation that is not adequately treated by currently available therapeutic regimens. This grant plans to study the underlying molecular mechanisms that can be used to down regulated NMDA receptor activity in aq clinically tolerant manner using a combination of techniques ranging from molecular biology and gene-targeting to patch-clamp recording. Two types of clinically tolerated NMDA antagonists are being developed: (1) open- channel blockers of the memantine class of compounds, and (2) nitric oxide (NO) related species (using nitroglycerin). Additional novel agents include a combinatorial drug, nitro-memantine, which targets NO species to NMDARs via the open-channel blocker. In projects, these novel, clinically-tolerated NMDA antagonists will be tested in animal models of hypoxic-ischemic and HIV-related brain injury. These projects will also explore signaling pathways downstream to NMDAR activity which mediate neuronal necrosis or apoptosis and involve nitric oxide and caspases. Rodent models consisting of transgenic and knockout mice will be used. Project has cloned, characterized and generated mice deficient in a new NMDAR subunit NR3A. The CORE supplies support for statistics, tissue culture, and magnetic resonance imaging/spectroscopy (MRI/MRS). An important feature of this Program Project is its multi-disciplinary approach using molecular biology, electrophysiology and imaging techniques both in vitro and in vivo. The team has a proven track record of hypothesis testing to help elucidate the pathogenesis of hypoxic-ischemic and AIDS-related injury in the brain, and then of using this knowledge for drug development, leading to human clinical studies.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
5P01HD029587-10
Application #
6526947
Study Section
Special Emphasis Panel (ZHD1-MRG-C (SL))
Program Officer
Oster-Granite, Mary Lou
Project Start
1992-09-01
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
10
Fiscal Year
2002
Total Cost
$1,658,754
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2018) Publisher Correction: Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 9:1070
Nagar, Saumya; Noveral, Sarah M; Trudler, Dorit et al. (2017) MEF2D haploinsufficiency downregulates the NRF2 pathway and renders photoreceptors susceptible to light-induced oxidative stress. Proc Natl Acad Sci U S A 114:E4048-E4056
Mann, Aman P; Scodeller, Pablo; Hussain, Sazid et al. (2017) Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun 8:1403
Tu, Shichun; Akhtar, Mohd Waseem; Escorihuela, Rosa Maria et al. (2017) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. Nat Commun 8:1488
Satoh, Takumi; Lipton, Stuart (2017) Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res 6:2138
Nakamura, Tomohiro; Lipton, Stuart A (2017) 'SNO'-Storms Compromise Protein Activity and Mitochondrial Metabolism in Neurodegenerative Disorders. Trends Endocrinol Metab 28:879-892
Chen, Shanyan; Cui, Jiankun; Jiang, Tao et al. (2017) Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke. J Cereb Blood Flow Metab 37:188-200
Nagar, Saumya; Trudler, Dorit; McKercher, Scott R et al. (2017) Molecular Pathway to Protection From Age-Dependent Photoreceptor Degeneration in Mef2 Deficiency. Invest Ophthalmol Vis Sci 58:3741-3749
Akhtar, Mohd Waseem; Sanz-Blasco, Sara; Dolatabadi, Nima et al. (2016) Elevated glucose and oligomeric ?-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Commun 7:10242
Sanz-Blasco, Sara; Piña-Crespo, Juan C; Zhang, Xiaofei et al. (2016) Levetiracetam inhibits oligomeric A?-induced glutamate release from human astrocytes. Neuroreport 27:705-9

Showing the most recent 10 out of 175 publications